July 2024: A new study, published on July 3, 2024, indicates patients taking semaglutide such as Wegovy may face an increased risk of serious eye injuries, including nonarteritic anterior ischemic optic neuropathy (NAION)
Get back to the best version of yourself with a holistic approach that focuses on what you put in your mouth, from oral care to your favorite treat
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently under clinical investigation and not yet approved by the MHRA or EMA
View options here: GLP-1 Pricing 6
Means lower Emerging observational studies and small interventional trials suggest that GLP-1 RAs may be used in patients with advanced CKD with preserved glucose-lowering efficacy and a relatively low intrinsic risk of hypoglycemia compared with insulin and sulfonylureas ( Semaglutide has recently received expanded regulatory approval for use in patients with T2DM and CKD, reflecting growing confidence in its renal safety profile and potential kidney-protective benefits ( In Saudi Arabia, T2DM prevalence is among the highest worldwide and is accompanied by high rates of obesity, cardiovascular disease, and CKD ( Therefore, this multicenter retrospective study aimed to evaluate the real-world safety and effectiveness of semaglutide in patients with ESRD receiving care at Saudi tertiary healthcare centers, with a focus on glycemic outcomes, body weight changes, cardiovascular events, renal safety, and treatment tolerability
